Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6701)
All Articles published online
|
Publishing Process of This Article
|
Nov 15, 2019 (publication date) through Dec 1, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Park SJ, Kim H, Shin K, Lee MA, Hong TH. Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. World J Gastrointest Oncol 2019; 11(11): 1021-1030 [PMID: 31798782 DOI: 10.4251/wjgo.v11.i11.1021] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v11/i11/1021.htm |
| Number | Citing Articles |
| 1 |
L. I. Moskvicheva, L. V. Bolotina. Possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancer. Research and Practical Medicine Journal 2020; 7(4): 118 doi: 10.17709/2409-2231-2020-7-4-10
|
| 2 |
Yanqiong Chen, Wei Zhang, Xiang Li, Bhagyaveni M.A. Analysis of the Management Effect of Cancer Patients after Oral Chemotherapy Based on Nursing Process Reengineering. Journal of Healthcare Engineering 2022; 2022: 1 doi: 10.1155/2022/4539125
|
| 3 |
Hakon Blomstrand, Atul Batra, Winson Y Cheung, Nils Oskar Elander. Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer. World Journal of Clinical Oncology 2021; 12(9): 787-799 doi: 10.5306/wjco.v12.i9.787
|
| 4 |
Muhammad Sardar, Alejandro Recio-Boiles, Kabir Mody, Christian Karime, Sreenivasa R Chandana, Daruka Mahadevan, Jason Starr, Jeremy Jones, Mitesh Borad, Hani Babiker. Pharmacotherapeutic options for pancreatic ductal adenocarcinoma. Expert Opinion on Pharmacotherapy 2022; 23(18): 2079 doi: 10.1080/14656566.2022.2149322
|
| 5 |
|
| 6 |
Jaime Feliu, Mónica Jorge Fernández, Teresa Macarulla, Bartomeu Massuti, Ana Albero, José Federico González González, Guillermo Quintero-Aldana, Juan Ignacio Delgado-Mingorance, Ana Fernández Montes, Carmen García Piernavieja, Manuel Valladares-Ayerbes, Ana María López Muñoz, Rebeca Mondéjar Solís, Pilar Vicente, Esther Casado Gonzalez, Irene González Cebrián, Guillermo López-Vivanco. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study. Cancer Chemotherapy and Pharmacology 2021; 87(4): 543 doi: 10.1007/s00280-020-04214-w
|
| 7 |
Y. E. Chikhareva, M. Yu. Fedyanin, I. S. Bazin, I. A. Pokataev, A. A. Tryakin. Systemic therapy for metastatic pancreatic cancer. Malignant tumours 2023; 13(4): 60 doi: 10.18027/2224-5057-2023-13-4-60-68
|
| 8 |
Alison Lewis, Adnan Nagrial. Systematic Review of Single-Agent vs. Multi-Agent Chemotherapy for Advanced Pancreatic Adenocarcinoma in Elderly vs. Younger Patients. Cancers 2023; 15(8): 2289 doi: 10.3390/cancers15082289
|
| 9 |
Xiaofei Zhu, Yangsen Cao, Mingzhi Lu, Xianzhi Zhao, Lingong Jiang, Yusheng Ye, Xiaoping Ju, Huojun Zhang. Stereotactic body radiation therapy with sequential S-1 for patients with locally advanced pancreatic cancer and poor performance status: An open-label, single-arm, phase 2 trial. Radiotherapy and Oncology 2021; 162: 178 doi: 10.1016/j.radonc.2021.07.009
|
| 10 |
Jingjing Xiao, Chao Lv, Chuan Xiao, Jinyu Ma, Jun Liao, Tao Liu, Jun Du, Shi Zuo, Haiyang Li, Huajian Gu. Construction of a ceRNA Network and Analysis of Tumor Immune Infiltration in Pancreatic Adenocarcinoma. Frontiers in Molecular Biosciences 2021; 8 doi: 10.3389/fmolb.2021.745409
|
| 11 |
Julia Salapa, Allison Bushman, Kevin Lowe, Joseph Irudayaraj. Nano drug delivery systems in upper gastrointestinal cancer therapy. Nano Convergence 2020; 7(1) doi: 10.1186/s40580-020-00247-2
|